Stylus Medicine, a startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes ...

Vir Biotech's hepatitis B therapy shows 4% cure rate with doublet (tobevibart/elebsiran) and 10% with triplet therapy, below ...

New data shows Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss, with 65% vs 40% of patients achieving ...

FDA clears Ensoma's trial of in vivo blood stem cell editing therapy for X-linked chronic granulomatous disease, following China's Yoltech earlier this year.

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back ...

President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...

Iovance Therapeutics’ stock dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales ...

Sarepta's stock falls 48% after FDA critic Vinay Prasad's appointment and poor Elevidys sales. Company cuts revenue forecast ...

FDA advisors to meet May 22 on Covid vaccine strain selection amid scrutiny from Kennedy's HHS, as Novavax awaits approval ...

The FDA announced a two-day meeting of its Oncologic Drugs Advisory Committee (ODAC) later this month to review cancer drugs ...

Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...

J&J's gene therapy bota-vec failed Phase 3 trial for X-linked retinitis pigmentosa vision loss. Follows trend of big pharma ...